Allarity Therapeutics, Inc. - Common stock (ALLR) earnings
ALLR earnings moved a median of -2.50% by the close. Quarterly and annual ALLR reports and results, each read against the price at its own news timestamp. Back to the ALLR overview →
20 measured ALLR earnings events.
Where these ALLR earnings landedvs 20 measured ALLR earnings reactions
| Middle 50% of ALLR earnings reactions | -5.33% to +1.65% |
|---|---|
| Median reaction (to close) | -2.50% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ALLR earnings events with a measured close landed between -5.33% and +1.65%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign | Press release | +0.00% | -2.84% | |
| Form 10-Q Allarity Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -2.84% | |
| Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers | Press release | +1.45% | +3.62% | |
| Form 10-Q Allarity Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.45% | +3.62% | |
| Form 10-K Allarity Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.01% | +6.86% | |
| Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates | Press release | +1.34% | +5.36% | |
| Form 10-Q Allarity Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.34% | +5.36% | |
| Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships | Press release | -2.26% | -2.14% | |
| Form 10-Q Allarity Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.26% | -2.14% | |
| Form NT 10-Q Allarity Therapeutics, For: Jun 30 | SEC filing · Form NT | -2.04% | -2.25% | |
| Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment | Press release | +2.97% | +0.99% | |
| Form 10-Q Allarity Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.97% | +0.99% | |
| Form 10-K Allarity Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.21% | -5.20% | |
| Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights | Press release | -1.38% | -2.76% | |
| Form 10-Q Allarity Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -4.80% | -5.71% | |
| Form 10-Q Allarity Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.30% | -5.83% | |
| Form 10-Q Allarity Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.41% | -7.22% | |
| Form 10-K/A Allarity Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -5.93% | |
| Form 10-K Allarity Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.04% | -3.23% | |
| Form 10-Q Allarity Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -5.20% | -6.80% |
Keep exploring
More ALLR: analyst actions → · SEC filings → · ALLR overview →